Site Archives
by page:
by month:
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
by post:
- Oramed cleared for oral insulin trials in U.S.
- Medigus to present three-year follow-up data of SRS pivotal study at DDW
- Stephens starts TearLab at overweight
- 2nd Annual Bloom Burton & Co. Healthcare Investor Conference; we’ll be there
- Analysts raise TearLab price targets
- Galena to target Abstral as market leader for cancer pain
- TearLab Q1 revenue jumps 486%
- Zalicus presents data on calcium channel blockers
- Cynapsus names Dexcel execs to its board
- Feltl analyst highlights Novadaq and TearLab in WSJ interview
- Orgenesis and ATMI in process development accord
- Zalicus in $25-million funding commitment
- Sucampo revenue rises 17% in Q1
- Dyadic names Danai Brooks as EVP and COO
- Oramed readies oral insulin study in U.S.
- William Blair starts Chimerix at outperform
- Byron Capital ups Cipher price target
- Cipher posts record first quarter results
- Pivotal’s George Jackowski receives QE II medal
- MLV starts Sucampo Pharma at buy
- Thomas Riedhammer joins Ohr Pharma board
- Novadaq selling $50.3-million of common shares
- Byron Capital lifts Transition price target
- Oramed diabetes data published in PLOS ONE
- William Ashton joins Galena Biopharma board
- Pivotal Therapeutics to present REVEAL data at ATVB
- Brainsway to launch Deep TMS in the U.S.
- Transition Therapeutics posts positive TT-401 results
- BioLineRx pipeline returns to the winner’s circle
- Oramed to present diabetes data today
- BioDelivery names Thomas D’Alonzo to board
- Novadaq Q1 revenue jumps 53%
- Tecnofarma to distribute Cipher’s tramadol
- BioLineRx starts Phase 1/2 hepatitis trial
- IntelGenx names Rajiv Khosla as COO, CSO
- FDA approves sNDA for Sucampo’s AMITIZA
- ASCRS 2013: TearLab gets another vote of confidence from prominent ophthalmologist
- Vaxil trial validates vaccine technology
- Senesco completes cohort 2 in Phase 1b/2a trial
- Ohr Pharma raises $5-million from warrant exercise
- Analysts: Early Novadaq PILLAR II data delivers
- Exact Sciences’ data disappoints analysts; highlights differences with GeneNews’ test
- Isotechnika updates investors on planned merger with Aurinia
- BioLineRx posts positive Phase 2a results in IBD
- David Dodd named CEO of Aeterna Zentaris
- Verisante distributor to launch Aura in Canada
- Oramed names Joshua Hexter as COO and VP of BD
- Stifel starts Tetraphase Pharma at buy
- DURECT files NDA for POSIDUR
- Stifel starts MEI Pharma at buy
- OnPoint’s Big-Data Equals Big Opportunity
- Janney initiates BioDelivery at buy
- Diabetes expert Dr. Jay Skyler joins Orgenesis’ SAB
- Oramed submits IND for U.S. oral insulin trial
- BioLineRx cleared for U.S. Phase 2a trial of BL-8040
- TearLab launches free smartphone IR app
- Pivotal’s VASCAZEN meets primary endpoint in REVEAL trial
- Vaxil posts positive therapeutic cancer vaccine results
- BioDelivery on track for mid-year NDA filing
- NovaBay ophthalmology study begins in Brazil
- Stifel Nicholas starts GTx at buy
- Islet Sciences gets U.S. patent claims allowance
- Stifel starts Novadaq at buy
- MDxHealth prostate research published in Journal of Oncopathology
- Cantor Fitzgerald starts Sucampo at buy
- Oramed gets Japanese patent for core technology
- Zalicus gets key formulation patent for Z160
- MDxHealth California lab gets ISO certification
- International Stem Cell scores neuronal goal in treating Parkinson’s
- Med BioGene partner renames lung cancer test
- Islet Sciences adds Dr. Eitan Akirav to SAB
- OncoGenex’s OGX-427 drug gaining investor attention
- Roth ups Galena price target to $7
- Ladenburg highlights market potential for MediciNova’s MN-166
- Analysts raise TearLab price targets
- Cynapsus closes second tranche of offering
- Ohr Pharma reports results of cancer cachexia trial
- MediciNova presenting MN-166 data at AAN
- Verisante distributor launches Aura in Germany
- Pluristem updates muscle injury trial
- TearLab revenue climbed more than three-fold in Q4
- Zalicus presents ion channel screening data
- Int’l Stem Cell reports positive Parkinson’s study results
- Data from epigenetic sequencing published in PLOS ONE
- Soricimed’s proof-of-concept published in journal
- Sucampo sees revenue from three continents by year end
- MethylGene posts disappointing trial results
- Gemoscan secures $10-million acquisition financing facility
- Galena to acquire Abstral sublingual tablets in U.S.
- NovaBay CEO interviewed on RedChip
- Int’l Stem Cell technology published in Nature-branded journal
- Novadaq moves to accelerate commercial launch of LUNA
- NovaBay blog post discusses crisis of antibiotic resistance
- Cynapsus continues prospectus offering
- Roth starts TG Therapeutics at buy
- Cardium’s To Go Brands expands VitaRocks line
- Islet Sciences points to study in Diabetes journal
- Roth starts Verastem at buy
- Galena gets Frost & Sullivan innovation award
- All eyes on Ohr Pharma wet AMD study
